Poland· PL-100474776
Opdualag
A nivolumab and relatlimab product containing niwolumab + relatlimab, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nivolumab and relatlimab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Nivolumab and relatlimab · ATC L01FY02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Niwolumab + Relatlimab
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Poland (PL)
- ATC code
- L01FY02
- ATC class
- Nivolumab and relatlimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08027950800476
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01FY02
Nivolumab and relatlimab, as other registers publish it.
- NorwayOpdualagBristol-Myers Squibb Pharma EEIG (1)
- IcelandOpdualagBristol-Myers Squibb Pharma EEIG*
- FinlandOpdualagBristol-Myers Squibb Pharma EEIG
- DenmarkOpdualagBristol-Myers Squibb Pharma EEIG
- CzechiaOPDUALAGBristol-Myers Squibb Pharma EEIG, Dublin
- United StatesOPDUALAGE.R. Squibb & Sons, L.L.C.
- CanadaOPDUALAGBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandOpdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3c80b6b4-58f5-426c-9e0b-4e0fc3be66de GET /v1/drugs/3c80b6b4-58f5-426c-9e0b-4e0fc3be66de?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "240 mg + 80 mg",
"packaging": "08027950800476 ¦ Rpz ¦ EU/1/22/1679/001 ¦ 147268\n1 fiol. 20 ml\n¦ UR/Z/4c/207/26 - 08027950800476 ¦ UR/Z/4c/217/26 - 08027950800476",
"substance": "Nivolumabum 240 mg + Relatlimabum 80 mg",
"common_name": "Niwolumab + Relatlimab",
"pl_product_id": "100474776",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nivolumab and relatlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.